Solutions

Online Inquiry

Name *

Email *

Phone *

Services Interested *

Project Description

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.

Therapeutic Monoclonal Antibody Development Services

Monoclonal antibodies (mAb) are considered unique biological tools and have been a standard component of cancer therapy. Alfa Cytology offers therapeutic monoclonal antibody development services to help clients develop better cancer therapies based on monoclonal antibodies.

Therapeutic Monoclonal Antibody for Cancer Therapy

As the basis of molecular cancer therapy, monoclonal antibodies offer a number of key advantages. As one of the most common classes of antibodies in the immune system, IgG binds to specific molecular epitopes and interacts with the effector arms of the immune system. IgG has a long half-life and is distributed in both intravascular and extravascular compartments. Anti-cancer monoclonal antibodies act through a variety of mechanisms.

2-3-2-1-therapeutic-monoclonal-antibody-development-services-1

Targeting Cancer Cells

MAb has been used to target a variety of antigens expressed on the surface of cancer cells. Some mAb targeting malignant cell surface antigens are capable of inducing apoptosis through direct transmembrane signaling. In addition, mAbs can kill target cells through complement-mediated cytotoxicity (CMC) and induction of antibody-dependent cytotoxicity (ADCC).

2-3-2-1-therapeutic-monoclonal-antibody-development-services-1

Altering the Host Response

Monoclonal antibodies in combination with cytotoxic drugs can induce cancer cell death by interfering with and inhibiting tumor neo-angiogenesis. Checkpoint-blocking mAb has been developed to interfere with the inhibitory signals responsible for limiting T-cell activation. In this way, it maintains the T-cell activation phenotype and enhances T-cell-mediated lysis to induce a more robust and sustained anti-tumor T-cell response.

Our Services

The characteristics of mAb that influence their efficacy include antigenic specificity, overall structure, and the affinity for the target antigen. Alfa Cytology has the expertise to drive the development of better mAb-based cancer therapies.

Antibody Discovery and Synthesis

Alfa Cytology helps you design and synthesize antibody candidates and deliver reliable antibody products.

Cell Line Development - Simplify cell line characterization with ddPCR using fewer samples.
High-throughput Antibody Screening - Maximize productivity with powerful and automated high-speed flow cytometry.
Monoclonal Antibody Purification - Obtain high quality monoclonal antibodies with the help of our experienced bioprocessing development scientists.

Candidate Characterization and Optimization

Alfa Cytology offers cost-effective and scalable solutions to help customers characterize and optimize candidates.

Immunogenicity Assessment - Involves the detection and quantification of anti-drug antibody (ADA) to help identify any immune responses that may affect their efficacy or safety.
Biodistribution Studies - Through advanced imaging and analytical methods, we can assess the tissue-specific accumulation, clearance, and retention properties of antibodies.
Toxicity Assessment - Evaluate the effects on vital organs, physiological functions, and systemic toxicity.
Functional Testing - Evaluates the ability of an antibody to modulate the host immune response.

Process Analysis and Development

Our services are designed to support the development of robust and scalable purification processes that ultimately facilitate the production of high-quality antibody products.

Impurity and Contamination Detection - Advanced methods are used to assess the presence of process-related impurities such as host cell proteins, DNA, endotoxins, aggregates, and other potential contaminants.
Chromatography and Purification Solutions - Includes the development and optimization of antibody purification strategies to achieve desired antibody purity, yield, and stability.

Workflow of Therapeutic Monoclonal Antibody Development

Target Identification

Identifying potential target molecules that are involved in the disease pathway through genomics and proteomics.

Target Validation

The identified targets are further validated to ensure their relevance and suitability as therapeutic targets.

Antibody Generation

Generation of specific anti-cancer antibodies using hybridoma technology, phage display, and transgenic animals.

Lead Antibody Selection

Functional assays and engineering techniques are applied to optimize their therapeutic potential.

Preclinical Studies

Efficacy, safety, pharmacokinetics, and pharmacodynamics are tested in relevant disease models.

Therapeutic monoclonal antibodies have long been one of the most promising cancer therapies. For scientists with extensive experience in therapeutic antibody discovery and development, Alfa Cytology can provide products, services, and support to help you generate actionable data quickly, confidently, and cost-effectively. Please contact us for more information.

For research use only.